Loading…
Lobbying Income
$1.3M
Filings
38
Unique Clients
4
Active Period
2013–2015
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: H. Con. Res. 27, H.Con.Res. 27
Hire More Heroes Act of 2015
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: H.J.Res 61
National Clinical Care Commission Act
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters HR 3742, Access to Marketplace Insurance Act
Client expense: — · Firm income: $22,500
Matched citations: HR 1192
Medicare Access and CHIP Reauthorization Act of 2015
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Client expense: — · Firm income: $22,500
Matched citations: HR 2
Consolidated Appropriations Act, 2016
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: HR 2029
Treat and Reduce Obesity Act of 2015
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Client expense: — · Firm income: $22,500
Matched citations: HR 2404
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters HR 3742, Access to Marketplace Insurance Act
Client expense: — · Firm income: $22,500
Matched citations: HR 3020
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: HR3020
To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: HR 3660
Access to Marketplace Insurance Act
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters HR 3742, Access to Marketplace Insurance Act
Client expense: — · Firm income: $22,500
Matched citations: HR 3742
21st Century Cures Act
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Client expense: — · Firm income: $22,500
Matched citations: HR 6
21st Century Cures Act
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 6 - 21st Century Cures Act FDA issues regarding biosimilar products; 340B program matters
Client expense: — · Firm income: $22,500
Matched citations: HR 6
Breast Density and Mammography Reporting Act of 2015
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: HR 716
Treat and Reduce Obesity Act of 2015
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Client expense: — · Firm income: $22,500
Matched citations: S 1509
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters HR 3742, Access to Marketplace Insurance Act
Client expense: — · Firm income: $22,500
Matched citations: S 1695
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: S 1695
National Diabetes Clinical Care Commission Act
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters HR 3742, Access to Marketplace Insurance Act
Client expense: — · Firm income: $22,500
Matched citations: S 586
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · fourth_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: S. Con. Res. 11
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: H. Con. Res. 27, H.Con.Res. 27
Hire More Heroes Act of 2015
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: H.J.Res 61
National Clinical Care Commission Act
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters Legislation (no bill number yet) regarding private not-for-profit foundations paying for health exchange premiums and cost sharing for certain individuals.
Client expense: — · Firm income: $22,500
Matched citations: HR 1192
Medicare Access and CHIP Reauthorization Act of 2015
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Client expense: — · Firm income: $22,500
Matched citations: HR 2
Treat and Reduce Obesity Act of 2015
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Client expense: — · Firm income: $22,500
Matched citations: HR 2404
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Client expense: — · Firm income: $22,500
Matched citations: HR3020
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
2015 · third_quarter · Client: NOVO NORDISK PHARMACEUTICALS, INC.
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters Legislation (no bill number yet) regarding private not-for-profit foundations paying for health exchange premiums and cost sharing for certain individuals.
Client expense: — · Firm income: $22,500
Matched citations: HR 3020
Source: Senate LDA